Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis

Abstract EN

Background.

Some studies have reported that renal dysfunction is associated with poor prognosis in cirrhotic patients.

Serum cystatin C (CysC) is an accurate biomarker for early renal dysfunction.

This study aimed to assess the prognostic value of serum CysC levels in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DeCi).

Methods.

This retrospective study included 75 subjects who had been diagnosed with HBV-DeCi.

The association between serum CysC and prognosis was estimated by receiver operating characteristic curve analysis and a multivariable logistic regression model.

Results.

Serum CysC levels were higher in nonsurvivors than in survivors and were positively correlated with model for end-stage liver disease (MELD) scores.

In multivariate analysis, CysC and the MELD score were independent prognostic factors in all HBV-DeCi patients.

However, only serum CysC was an independent factor predicting mortality in patients with normal creatinine levels.

Conclusions.

These data suggest that high serum CysC levels can be considered an independent biomarker of 3-month mortality in patients with HBV-DeCi.